Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT2 | O60551 | 1/20 | 0.52 |
| ▸ | NMT1 | P30419 | 1/20 | 0.52 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.51 |
| ▸ | GLP1R | P43220 | 8/20 | 0.51 |
| ▸ | TLR2 | O60603 | 1/20 | 0.50 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.46 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | CASP2 | P42575 | 1/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19156036 | 1.00 | NMT2 (0.52) | NMT2NMT1NOD1GLP1RTLR2 | |
| SCHEMBL22692638 | 0.99 | NMT2 (0.50) | NMT2NMT1NOD1GLP1RTLR2 | |
| SCHEMBL21154993 | 0.99 | NMT2 (0.50) | NMT2NMT1NOD1GLP1RTLR2 | |
| SCHEMBL22692615 | 0.95 | NMT2 (0.47) | NMT2NMT1NOD1GLP1RTLR2 | |
| SCHEMBL18513227 | 0.94 | NMT1 (0.54) | NMT2NMT1NOD1GLP1RTLR2 | |
| SCHEMBL22692704 | 0.91 | NMT2 (0.50) | NMT2NMT1NOD1GLP1RTLR2 | |
| SCHEMBL20643468 | 0.90 | NMT2 (0.48) | NMT2NMT1NOD1GLP1RTLR2 | |
| SCHEMBL22692618 | 0.89 | NMT2 (0.53) | NMT2NMT1NOD1GLP1RTLR2 | |
| SCHEMBL24645937 | 0.89 | NMT2 (0.52) | NMT2NMT1NOD1GLP1RTLR2 | |
| SCHEMBL19062765 | 0.88 | NMT1 (0.49) | NMT2NMT1NOD1GLP1RTLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200224198-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200224198-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | HAVCR2, HCCS, HDGF | NMT2 132/4885NMT1 85/4885NOD1 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.